Boston Properties, Inc. (NYSE: BXP), a real estate investment trust,
announced today that its Board of Directors declared a regular quarterly
cash dividend of $0.65 per share of common stock for the period October
1, 2014 to December 31, 2014 payable on January 28, 2015 to shareholders
of record as of the close of business on December 31, 2014.
plc (NYSE: MNK) has been informed by the U.S. Food and Drug
Administration (FDA) that the agency has reason to believe that the
company’s methylphenidate hydrochloride extended-release (ER) tablets,
USP (CII) may not be therapeutically equivalent to the category
reference drug Concerta®. As a result, the agency indicated that it has
reclassified Mallinckrodt’s ANDA 202608 for methylphenidate ER dosage
strengths of 27mg, 36 mg and 54 mg from AB (freely substitutable at the
pharmacy level) to BX (presumed to be therapeutically inequivalent). The
agency said that this change was based on the application of its new
Draft Guidance for determining bioequivalence of methylphenidate
hydrochloride products just published on November 6, 2014.
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy to be Approved by the FDA BLINCYTO (Blinatumomab) for Injection Will be Available as a 35 mcg Single use Vial
THOUSAND OAKS, Calif.
Pro Forma Results: - Adjusted Net Income of $35.5 Million or $0.40 per Fully Diluted Share for the Third Quarter; $116.2 Million or $1.31 per Fully Diluted Share for the First Nine Months 2014
- Adjusted EBITDA of $57.8 Million for the Third Quarter; $193.7 Million for the First Nine Months 2014 Assets Under Administration of $212.8 Billion; up 11.3% From the Year Ago Period Following Review by Independent External Counsel and Forensic Accounting Firm, RCS Capital's Audit Committee and Management Team Remain Confident in The Company's Reported Historical Financials, Accounting, and Internal Controls $57 - $65 Million Revenue Synergies and Cost Savings Expected to be in Place for January 1, 2015; Additional Synergies Expected in 2015 9,139 Total Advisors on Platform; 97.8% Annualized Advisor Retention; Solid Retail Margin Expansion in Third Quarter; Robust Recruiting Pipeline Wholesale Distribution Equity Sales of $2.3 Billion for the Third Quarter; $8.2
Exchange Traded Funds, sponsored and managed by Northern Trust, today
introduced FlexShares Credit‐Scored US Corporate Bond Index Fund
(Nasdaq: SKOR), a fixed income portfolio consisting of corporate debt
securities selected using a proprietary credit evaluation process.
Lineup includes New Snickerdoodle Cookie and Sugar Cookie Flavors, as well as returning favorite Peppermint Mocha Guests can enter to win a $500 shopping spree with a loved one through Dunkin' Donuts' #ThanksaLatte Twitter Sweepstakes in the Metro New York area*
NEW YORK , Nov.
Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to existing exclusivity, Fast-Track status (an expedited development pathway) and Priority Review status (shortened review time for marketing applications) With half of the targeted 120 patients already recruited, top-line data from the ongoing RHB-105 first Phase III study in the U.S. is expected in the second quarter of 2015 RHB-105 is targeting a significantly broader indication than that of existing H.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from
several Phase 2 and Phase 3 studies evaluating investigational uses of
Harvoni ® (ledipasvir 90 mg/sofosbuvir 400 mg) for the
treatment of chronic hepatitis C virus (HCV) infection in patients with
limited or no treatment options, including patients with decompensated
cirrhosis, patients with HCV recurrence following a liver transplant and
patients who failed previous treatment with other direct acting
Vanguard Natural Resources, LLC (NASDAQ: VNR) (“Vanguard”) has declared
a cash distribution attributable to the month of October 2014 of $0.21
per unit ($2.52 on an annual basis) payable on December 15, 2014 to
unitholders of record on December 1, 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.